Evidence map›Paper›PMID 35744605›Full record

ArticleMicroorganisms2022

Overcoming Poor Transgene Expression in the Wild-Type

Obed W Odom, Seongjoon Kang, Caleb Ferguson, Carrie Chen, David L Herrin

Abstract read
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Obed W OdomDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
Seongjoon KangPond Life Technologies LLC, Cedar Park, TX 78613, USA.
Caleb FergusonDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
Carrie ChenDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.
David L HerrinDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA.ORCID 0000-0002-9082-6820

Funding

Green Algal Strains for Biological Control of West Nile Virus MosquitoesR41AI115854 · NIAID · POND LIFE TECHNOLOGIES, LLC · PI HERRIN, DAVID L · 2015 to 2015
$150k
NIAID NIH HHS R41 AI115854NIH HHS R41-AI115854A
6 · The paper itself

Abstract

High-level expression of transgenes in the chloroplast of wild-type Chlamydomonas reinhardtii (C. reinhardtii) remains challenging for many genes (e.g., the cry toxin genes from Bacillus thuringiensis israelensis). The bottleneck is presumed to be post-transcriptional and mediated by the 5′ element and the coding region. Using 5′ elements from highly expressed photosynthesis genes such as atpA did not improve the outcome with cry11A regardless of the promoter. However, when we employed the 5′ UTR from mature rps4 mRNA with clean fusions to promoters, production of the rCry11A protein became largely promoter-dependent. The best results were obtained with the native 16S rrn promoter (−91 to −1). When it was fused to the mature 5′ rps4 UTR, rCry11A protein levels were ~50% higher than was obtained with the inducible system, or ~0.6% of total protein. This level was sufficient to visualize the 73-kDa rCry11A protein on Coomassie-stained gels of total algal protein. In addition, analysis of the expression of these transgenes by RT-PCR indicated that RNA levels roughly correlated with protein production. Live cell bioassays using the best strains as food for 3rd instar Aedes aegypti larvae showed that most larvae were killed even when the cell concentration was as low as 2 × 104 cells/mL. Finally, the results indicate that these highly toxic strains are also quite stable, and thus represent a key milestone in using C. reinhardtii for mosquito control.

Indexed as

Aedes aegyptibiolarvacideChlamydomonas reinhardtiichloroplast engineeringcry11Aagreen microalga

Identifiers

PMID35744605
PMCPMC9229432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.